Objective: To assess the safety and efficacy of two, single-tablet regimens for the initial treatment of HIV infection.
Results: Participants receiving EVG/COBI/FTC/TDF exhibited a more rapid decline in HIV-1 RNA and a greater proportion suppressed viral load to less than 50 copies/ml than participants receiving EFV/FTC/TDF. Both EVG/COBI/FTC/TDF and EFV/FTC/TDF resulted in high rates of viral suppression and increases in CD4 cell count. Ninety and 83% of participants suppressed HIV-1 RNA to less than 50 copies/ml both at the 24-week and 48-week visits for EVG/COBI/FTC/TDF and EFV/FTC/TDF, respectively. Once-daily administration of EVG/COBI/FTC/TDF provided a mean EVG trough concentration 10-fold over its protein binding-adjusted IC 95 across study visits. EVG/FTC/ TDF/GS-9350 was generally well tolerated with a lower rate of drug-related central nervous system (17%) and psychiatric (10%) adverse events versus EFV/FTC/TDF (26 and 44%, respectively) . Decreases in estimated glomerular filtration rate occurred within the first few weeks of dosing in participants receiving EVG/COBI/FTC/TDF, remained within the normal range and did not progress at week 24 or 48; no participant experienced a clinical adverse event or discontinued study drug due to changes in serum creatinine or renal function.
Introduction
Historically, international treatment guidelines recommend initial therapy for treatment-naive, HIV-infected patients be composed of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and either a nonnucleoside reverse transcriptase inhibitor (NNRTI)usually efavirenz (EFV) -or a ritonavir-boosted protease inhibitor (PI/r) [1] [2] [3] . Recently, an integrase inhibitorbased regimen was added as a preferred regimen by some guidelines [1, 2] . Although current regimens have been successful in reducing the morbidity/mortality associated with HIV disease, most require multiple pills, have sideeffects and often, require twice-daily dosing. Dosing frequency and pill burden remain key obstacles to patients maintaining long-term adherence needed to avoid treatment failure and subsequent use of more inconvenient, less well tolerated and ultimately more expensive regimens [4] [5] [6] [7] [8] [9] . There remains a need for new antiretroviral agents with improved safety profiles and simplified, once-daily single-tablet regimens (STRs) for the treatment of HIV infection. Elvitegravir (EVG) is an HIV-1 strand-transfer integrase inhibitor with potent in-vitro and in-vivo activity [10, 11] . EVG is metabolized via cytochrome P450 (CYP) 3A4; thus, co-administration with potent CYP3A inhibitors such as ritonavir or the investigational pharmacoenhancer cobicistat (GS-9350, COBI) substantially increases ('boost') its systemic exposure, including providing high trough (C min ) concentrations and allowing for once-daily dosing [12] [13] [14] . EVG has been generally well tolerated in clinical studies and at this time is under phase 3 evaluation in treatment-naive and treatment-experienced patients [15] .
Liabilities of low-dose ritonavir include adverse events and intolerance by some patients, physicochemical properties that limit coformulation potential with other antiretrovirals and the need for an additional prescription for patients [16] . COBI is devoid of anti-HIV activity with less negative effects on adipocyte function in vitro and can be coformulated with other agents requiring boosting, including EVG and protease inhibitors [17] .
The co-formulation of EVG with COBI and the standard-of-care NRTI backbone emtricitabine/tenofo-vir disoproxil fumarate (FTC/TDF) into a STR has been described previously [17, 18] . We now report the results of a 48-week, randomized, double-blind, multicenter, active-controlled study of two once-daily STRs: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; 'Quad') versus efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF, Atripla) in HIV-1-infected, antiretroviral treatment-naive adult participants [19, 20] .
Methods

Study design
Key entry criteria were adults (!18 years) with a screening plasma HIV-1 RNA of at least 5000 copies/ml and a CD4 cell count more than 50 cells/ml, no prior use of any approved or experimental anti-HIV drug and no NRTI, NNRTI or primary protease inhibitor genotypic resistance mutations [by International AIDS Society (IAS)-USA guidelines], normal ECG, estimated creatinine clearance (glomerular filtration rate, eGFR; Cockcroft-Gault) at least 80 ml/min, aspartate aminotransferase/alanine aminotranferease (AST/ALT) 2.5 times or less the upper limit of normal (ULN) and total bilirubin 1.5 mg/dl or less and a negative serum pregnancy test (as applicable). Participants were excluded if they were hepatitis B or C-coinfected, exhibited a new AIDS-defining condition within 30 days of screening or vaccination within 90 days of study drug dosing. The study was conducted in the United States from March 2009 (screening opening and closing) through March 2010 (48-week visits) under Good Clinical Practice and Institutional Review Boards' review. Prior to study screening, all participants signed written informed consent. This study was posted on clinicaltrials.gov (NCT00869557).
Eligible participants were randomized centrally by a third party interactive voice/web response system, stratified by screening HIV-1 RNA level ( or >100 000 copies/ml) in a 2 : 1 manner (block size of 6) to treatment with either EVG/COBI/FTC/TDF administered once-daily with food (n ¼ 50) or EFV/FTC/TDF at bedtime (n ¼ 25); participants received placebo tablets matching the alternate treatment. All parties involved in the study (patients, care providers and site, CRO and Sponsor staff) were blinded to treatment.
Study visits occurred at screening, baseline and weeks 2, 4, 8, 12, 16, and then every 8 weeks through week 48. Laboratory analyses (hematology, serum chemistries and urinalysis; Covance Laboratories, Indianapolis, Indiana, USA), HIV-1 RNA (AMPLICOR HIV-1 Monitor assays; Roche Molecular Systems, Pleasanton, California, USA) and physical examinations were performed at all study visits. HIV-1 genotype (reverse transcriptase and protease) was analyzed at screening (Covance Laboratories). Reverse transcriptase and protease (PhenoSense GT Assay) and integrase inhibitor (PhenoSense Integrase Assay, Monogram Biosciences, South San Francisco, California, USA) resistance testing was performed on participants with HIV-1 RNA more than 400 copies/ml at week 24 or 48 or upon early discontinuation of study drugs. Single time-point blood draws were collected in all participants/visits with targeted trough samples (collected 20-25 h post-EVG/COBI/FTC/TDF dose) obtained at weeks 8, 24 and 48; a pharmacokinetic substudy was conducted at week 2.
Statistical methods
The primary analysis objective was the efficacy of EVG/ COBI/FTC/TDF versus EFV/FTC/TDF as determined by viral suppression defined as HIV-1 RNA less than 50 copies/ml at week 24. Secondary objectives were the safety and tolerability of the regimens and viral suppression through week 48. Primary efficacy analyses were intent-to-treat, missing equals failure (ITT, M ¼ F). This study was not powered for efficacy comparisons between treatments; however, an a priori planned analysis included the point estimate of treatment difference and the associated two-sided 95% confidence interval (CI) in the response rates, stratified by baseline HIV-1 RNA. All patients who took at least one dose of study drugs were included in the analysis of safety and tolerability that included adverse events and laboratory abnormalities occurring within 30 days of study drug discontinuation.
Results
Seventy-one participants were randomized and received study drugs. Baseline demographics and disease characteristics were similar (P > 0.1) between the two treatment groups. Ninety-two (92) percent of participants were men, mean (SD) age was 36 (9.1) years, 24% of participants were black, 72% were white and approximately 10% self-identified as Hispanic. Mean (SD) weight and BMI were 82 (13) kg and 26.5 (3.9) kg/m 2 , respectively. Mean HIV-1 RNA level at baseline was 4.59 log 10 copies/ml; the median CD4 cell count was 394 cells/ml. Sixty-five (92%) participants were on blinded study drug through week 24 and remained so through week 48.
Treatment with EVG/COBI/FTC/TDF was associated with more rapid achievement of HIV-1 RNA less than 50 copies/ml than EFV/FTC/TDF (P < 0.05 at weeks 2, 4 and 8; Fig. 1 ). The proportions of participants with plasma HIV-1 RNA less than 50 copies/ml at week 24 were 90% (43/48) in the EVG/COBI/FTC/TDF group and 83% (19/23) in the EFV/FTC/TDF group (ITT M ¼ F). At week 48, response rates for HIV-1 RNA were identical to those at week 24 for both treatment arms, with 90 and 83% of participants with viral suppression to less than 50 copies/ml. The stratum-weighted difference (95% CI) in response rates between the two treatment groups (EVG/COBI/FTC/TDF -EFV/FTC/TDF) was þ5.0% (À11 to þ21.1%) at week 24 and þ8.4% (À8.8 to þ25.6%) at week 48. Greater than 95% of participants on study drugs (ITT Missing ¼ Excluded) in both treatment arms were suppressed to less than 50 copies/ml at both weeks 24 and 48. All unsuppressed participants at week 48 (n ¼ 3) were suppressed to less than 50 copies/ml at their subsequent study visit. One of these participant experienced confirmed virologic rebound in HIV-1 RNA at the week 48 visit secondary to documented noncompliance to study drugs based on return of unused study medication at study visits. This participant was receiving and continued treatment on study with EFV/FTC/TDF and re-suppressed HIV-1 RNA to less than 50 copies/ml at the next study visit.
In participants receiving EVG/COBI/FTC/TDF, greater than 90% of EVG trough concentrations (C min ) across all visits were above the protein binding-adjusted IC 95 with a mean C min to protein-binding adjusted IC 95 ratio ('IQ 95 ') of 10-fold. Results were similar in participants participating in the intensive pharmacokinetic substudy at week 2 (mean IQ 95 : 9.4, n ¼ 12) and all participants in the study In these participants, individual EVG concentrations were either more than three-fold (n ¼ 4 participants) above the protein binding-adjusted IC 50 or below the limit of quantitation (BLQ, 20 ng/ml; n ¼ 6 participants).
Treatment with EVG/COBI/FTC/TDF resulted in a median increase in CD4 cell count of 123 and 205 cells/ml baseline to week 24 and 48, respectively versus 124 and 139 cells/ml for the EFV/FTC/TDF group.
Six participants, three in each arm, discontinued study drug prematurely, all within the first 24 weeks. One participant receiving EFV/FTC/TDF discontinued study drug due to an adverse event (suicidal ideation) that was assessed as moderate in severity and related to study drug. No participant receiving EVG/COBI/FTC/TDF discontinued for an adverse event. Three participants were lost to follow-up, one withdrew consent and the final participant was discontinued by the investigator due to failure to return for study visits. HIV integrase inhibitors and robust COBI-boosted EVG exposures in virtually all participants and visits [21, 22] . No participants experienced virologic failure with this once-daily STR.
Safety data demonstrated that EVG/COBI/FTC/TDF tablets, dosed daily for up to 48 weeks, were generally well tolerated with no discontinuations due to adverse events or laboratory toxicities. Fewer participants receiving EVG/COBI/FTC/TDF experienced nervous system or psychiatric symptoms that are commonly reported by patients receiving a regimen that includes EFV [23] [24] [25] [26] [27] [28] [29] [30] . Decreases in eGFR occurred within the first few weeks of dosing in participants receiving EVG/ COBI/FTC/TDF which did not progress at either week 24 or 48. A pharmacokinetic/pharmacodynamic study has shown that administration of COBI results in small increases in serum creatinine but does not affect actual glomerular filtration rate when measured with a probe drug iohexol (data on file; Gilead Sciences Inc., Foster City, California, USA). These data indicate the observed increase in serum creatinine is due to an effect on the tubular secretion of serum creatinine.
High rates of efficacy and a favorable safety profile are required for any treatment regimen in the modern era. EFV is associated with central nervous system and psychiatric side-effects and hyperlipidemia; it may cause fetal harm when administered during the first trimester (pregnancy category D), thus limiting its use in women of childbearing potential. Some patients experience poor gastrointestinal tolerability and/or hyperlipidemia and are required to take three to four pills per day with boosted protease inhibitor-based regimes [16] . These phase 2 results support the ongoing evaluation of this once-daily STR of EVG/COBI/FTC/TDF as a potential attractive alternative for treatment-naive patients relative to currently available therapies, including the only currently available STR EFV/FTC/TDF. Week 2 À13.1 (À9%) À1.1 (À1%) Week 24
À18.0 (À13%) À6.6 (À5%) Week 48 À19.7 (À14%) À5.5 (À4%) AE, adverse event; eGFR, estimated glomerular filtration rate. 
